Epigenetic Editing Emerges as a Precision Strategy to Overcome Cancer Therapy Resistance
Key Insights
Epigenetic plasticity, including aberrant DNA methylation and histone modifications, is a central driver of therapy resistance across multiple cancer types.
CRISPR-based epigenetic editing tools such as dCas9 fused to catalytic domains enable precise, locus-specific rewriting of chromatin states to reverse resistance phenotypes.
Preclinical studies demonstrate that targeting epigenetic regulators like EZH2 (search), HDACs, and m6A modifiers can restore drug sensitivity and enhance immunotherapy responses.
Therapy resistance remains one of the most formidable challenges in oncology, with a substantial proportion of patients experiencing disease relapse driven by resistant cell populations despite advances in targeted therapies, immunotherapies, and chemotherapy. Emerging evidence now positions the epigenome as a central mediator of this resistance, and a new frontier—epigenetic editing—offers a transformative approach to address the problem with unprecedented precision.
Unlike conventional epigenetic drugs that act broadly across the genome, programmable epigenetic tools such as dCas9 fused to catalytic effector domains can rewrite chromatin states at specific loci. This allows researchers to silence oncogenic programs, reactivate silenced tumor suppressors, and reverse the transcriptional rewiring that underpins acquired or intrinsic resistance phenotypes.
The Epigenetic Basis of Drug Resistance
Cancer cells exploit chromatin remodeling, aberrant DNA methylation, and dysregulated histone modifications to evade treatment pressure and sustain proliferative survival. As noted in a comprehensive review published in Acta Pharmacologica Sinica, the epigenome serves as a critical interface between genetic predisposition and environmental adaptation in drug-resistant cancers.
DNA methylation plays a particularly important role. Geissler and colleagues highlighted that aberrant DNA methylation contributes to cancer initiation and has significant clinical impacts. In ovarian carcinoma (search), methylation of all BRCA1 copies was shown to predict response to the PARP inhibitor rucaparib, as demonstrated by Kondrashova et al. in Nature Communications. Similarly, epigenetic inactivation of SLFN11 (search), a putative DNA/RNA helicase, was found to confer resistance to platinum drugs, though class I histone deacetylase inhibitors could overcome this resistance by reactivating SLFN11 expression.
Histone modifications also drive resistance phenotypes. Jin and Jeong described how histone modifications in drug-resistant cancers operate from both cancer stem cell and immune evasion perspectives. For instance, BET protein inhibition was shown to sensitize glioblastoma (search) cells to temozolomide by attenuating MGMT expression, while EZH2 (search)-mediated transcriptional programs were implicated in driving neuroendocrine prostate cancer (search).
CRISPR-Based Epigenetic Editing: Precision Tools
The development of CRISPR-based epigenetic editors—including CRISPRa (activation), CRISPRi (interference), and base editing platforms—has opened new possibilities for cancer research. Hilton and colleagues demonstrated in Nature Biotechnology that a CRISPR-Cas9-based acetyltransferase could activate genes from promoters and enhancers. Thakore et al. subsequently showed in Nature Methods that CRISPR-Cas9 repressors could achieve highly specific epigenome editing for silencing distal regulatory elements.
Nakamura and colleagues provided a comprehensive overview in Nature Cell Biology, detailing how these technologies enable precise epigenome editing. The key advantage is locus specificity: rather than globally altering the epigenome with small-molecule inhibitors, these tools can target individual regulatory elements controlling resistance-associated genes.
Noncoding RNAs and RNA Modifications in Resistance
Beyond DNA and histone modifications, noncoding RNAs and epitranscriptomic changes contribute to therapy resistance. Wang and colleagues reviewed how noncoding RNAs—including long noncoding RNAs, microRNAs, and circular RNAs—mediate drug resistance. Qu et al. demonstrated in Cancer Cell that exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer (search) by acting as a competing endogenous RNA.
The m6A RNA modification landscape has also emerged as a critical factor. Uddin and colleagues described challenges and opportunities in targeting m6A modification for cancer therapy resistance. Yang et al. showed that the m6A demethylase FTO (search) regulates melanoma (search) tumorigenicity and response to anti-PD-1 blockade, while Li et al. found that METTL3 (search) promotes oxaliplatin resistance in gastric cancer (search) stem cells by stabilizing PARP1 mRNA.
Immunotherapy Resistance and Epigenetic Reversal
Epigenetic mechanisms also underpin resistance to PD-1/PD-L1 blockade immunotherapy. Dai and colleagues reviewed how epigenetic regulation contributes to immunotherapy resistance and highlighted therapeutic opportunities. Zingg et al. demonstrated in Cell Reports that the histone methyltransferase EZH2 (search) controls mechanisms of adaptive resistance to tumor immunotherapy. James and colleagues further showed that polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma (search) cells and is associated with anti-PD-1 resistance.
Importantly, epigenetic reprogramming extends to T cells themselves. Philip et al. reported in Nature that chromatin states define tumor-specific T cell dysfunction and reprogramming. Pauken and colleagues demonstrated in Science that epigenetic stability of exhausted T cells limits the durability of reinvigoration by PD-1 blockade. However, Liu et al. showed in Nature Communications that LSD1 inhibition can sustain T cell invigoration with a durable response to PD-1 blockade, suggesting that combining epigenetic modifiers with checkpoint inhibitors may overcome these barriers.
Clinical Translation and Delivery Challenges
Several epigenetic drugs have already entered clinical practice. Tazemetostat, an EZH2 (search) inhibitor, has been approved for certain malignancies. HDAC (search) inhibitors are being explored for overcoming drug resistance in castration-resistant prostate cancer (search). Tsai and colleagues demonstrated that transient low doses of DNA-demethylating agents can exert durable antitumor effects on both hematological and epithelial tumor cells.
However, translating epigenetic editing tools into clinical applications faces significant hurdles. Delivery strategies for in vivo applications—including nanoparticle and viral vector systems—require further optimization. Ethical, safety, and off-target considerations unique to therapeutic epigenome editing in cancer must be carefully addressed.
Future Directions
The convergence of mechanistic insight and therapeutic innovation is accelerating the path from bench to clinic. A dedicated Research Topic in Frontiers aims to consolidate knowledge at the intersection of epigenetic editing and cancer therapy resistance, covering mechanisms of epigenetic dysregulation, development of CRISPR-based editors, biomarker identification, preclinical studies, delivery strategies, and combination approaches.
As Davalos and Esteller noted in CA: A Cancer Journal for Clinicians, cancer epigenetics is increasingly entering clinical practice, with epigenetic biomarkers and therapies offering new avenues for personalized oncology. The ability to precisely edit the epigenome may ultimately transform how clinicians address the pervasive challenge of therapy resistance.